Navigation Links
Despite the risks, mephedrone users in the UK are ready to try the next legal high
Date:1/18/2012

Since mephedrone was made illegal in the UK in 2010, the street price of the drug has risen while the quality has degraded, which in turn may have reduced use of the drug. New research published online today reveals that young people who continued to use mephedrone after it became illegal would switch to a new legal high if it were pure and rated highly by their friends or on the Internet. They would be less deterred by a lack of scientific research on the new drug.

Mephedrone is a synthetic stimulant -- a 'designer drug' -- that became widely used in the UK from 2008 to 2010. Its rise in popularity may have been caused by its legality and ready availability (typically sold online as 'plant food'), and also to the reduced purity of street cocaine and ecstasy during the same period. In 2010, because of its similarity to amphetamines and frenzied media reporting of the harmful effects of the drug, mephedrone was made illegal in the UK and scheduled as a Class B drug. The drug is still available through street dealers and online.

Research published online today in the journal Addiction shows that after taking mephedrone, users showed impaired working memory as well as the typical stimulant drug effects of euphoria, self confidence and buzzing.

While intoxicated, they also experienced marked craving for mephedrone and typically binged on the drug, taking it repeatedly for an average of eight hours. When drug-free, this group showed higher levels of depression and poorer long term memory compared to controls using drugs other than mephedrone.

When asked what factors might influence them to try a new legal high, the same users said they would be drawn to a new drug that was pure and had few short-term or long-term harms. While they would be attracted by positive reports from friends and on the Internet, lack of scientific research on the drug and its legal status were less important factors.

Mephedrone has been the most publicized 'legal high' in recent years, but there are many new compounds currently emerging on Internet markets. In 2010, 41 new substances were detected in the EU, compared with 24 in 2009 and 13 in 2008. Of those 41 new substances, 15 are synthetic stimulants, just like mephedrone. One of these may become the new 'legal high' that current mephedrone users want.

Says lead researcher Tom Freeman of University College London, "Drug users today are attracted to new substances that are pure and have few adverse effects. Lack of scientific research on the effects and risks of new legal highs might explain why young people rely on subjective reports from friends or the Internet when deciding whether to try a new substance. Internet reports may be biased and offer an opportunity for drug vendors to promote their products. As well as encouraging new research, an important harm reduction strategy is for the media and advice websites such as FRANK to provide balanced and up-to-date information on these drugs."


'/>"/>

Contact: Jean O'Reilly
jean@addictionjournal.org
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
3. Firmex Achieves 237% Annual Revenue Growth Despite Tough M&A Environment in 2009
4. FDA Approved Diabetes Drug Despite Hints at Cancer Risk
5. Survey: Toyota owners maintain high overall satisfaction despite recalls
6. Exploitation of Overseas Nannies and Caregivers Could Continue Despite New Canadian Immigration Laws
7. Despite much-higher poverty rates, rural Oregonians use less public assistance
8. Complex Spinal Operations Soar Despite Drawbacks
9. Despite tests, high blood pressure hard to recognize in children
10. A Tan Is Still Admired, Despite Risks
11. Lung disease may be genetic, despite lack of family history
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... 2017 , ... East Los Angeles dentist, Ramin Assili DDS , comments ... happens to a woman during pregnancy can have profound effects on a developing fetus, ... on a baby’s long-term health. This study, which was performed at the University of ...
(Date:6/26/2017)... Torrance, CA (PRWEB) , ... June 26, 2017 , ... ... treatments. Smile aesthetics can be one of the most noticeable aspects of a person’s ... approachable. While not everyone is born with beautiful, balanced teeth, everyone can have the ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... & Sexual Medicine Specialists, in collaboration with the Fertility Center of California, is ... care: PESA (percutaneous epidydimal sperm aspiration) and TESA (percutaneous testicular sperm extraction). These ...
(Date:6/26/2017)... SALISBURY, MD. (PRWEB) , ... June 26, 2017 ... ... their crop, according to a recent review of government data released by the ... continuous improvement in management practices, Maryland’s soybean farmers have increased their productivity on ...
(Date:6/26/2017)... Lake Tahoe, CA (PRWEB) , ... June 26, 2017 , ... ... seeking 10,000 qualified mental health professionals in every state across the country to join ... an easy and rewarding way for therapists to reach a substantially greater number of ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... -- Less than a month ago, amateur hackers executed an ... hospital networks, in over 150 countries. The ... online extortion attempts ever recorded. With the increasing complexity ... that providers understand where the risks lie, and how ... many other very real cyber threats.  ...
(Date:6/7/2017)... GAITHERSBURG, Md. , June 7, 2017  Novavax, Inc., ... the second of two Phase 2 trials of its RSV ... women of child bearing age have been published in the ... this publication have been shared in prior scientific conferences). The ... trial in April 2014. Novavax is developing the RSV F ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
Breaking Medicine Technology: